ArticlebioRxiv : the preprint server for biology2026
Molecular Determinants of Allosteric Inhibitor Affinity and Selectivity in PDE5.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Allosteric inhibitors targeting unique regulatory pockets provide an opportunity for selective modulation of proteins within the phosphodiesterase (PDE) family. In this work, we investigate the molecular determinants for binding of an evodiamine derivative (EVO) to PDE5 and the structural basis for differential recognition of this inhibitor in PDE6 isoforms. We integrated structural modeling, all-atom molecular dynamics (MD) simulations, and extensive alchemical free-energy calculations to quantify residue-level contributions to inhibitor binding in PDE5 through systematic alanine scanning and PDE6-derived mutations. Thermodynamic analysis based on free energy identified key residues that govern EVO binding through a network of hydrogen bonds and hydrophobic contacts. Specifically, we examined structural changes associated with allosteric pocket variations in PDE5, identified key structural elements, and evaluated the role of chemical substituents of EVO in allosteric inhibition. Moreover, PDE6-derived substitutions revealed isoform specific effects, with PDE6-rod substitutions resulting in stronger destabilization than PDE6-cone substitutions. Together, these results define the energetic and structural basis for allosteric inhibition of PDE5 and provide mechanistic insights for the rational design of selective PDE inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.